Outpatients prescribed with fluvoxamine around the time of COVID-19 diagnosis are not at a reduced risk of subsequent hospitalization and death compared to their non-prescribed peers: population-based matched cohort study

PURPOSE: To assess the effect of exposure to fluvoxamine around the COVID-19 diagnosis on subsequent hospitalizations and mortality in COVID-19 outpatients in a real-life setting. METHODS: Using nationwide administrative data, we identified adult COVID-19 outpatients diagnosed up to August 15, 2021...

Descripción completa

Detalles Bibliográficos
Autores principales: Trkulja, Vladimir, Kodvanj, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036980/
https://www.ncbi.nlm.nih.gov/pubmed/36961578
http://dx.doi.org/10.1007/s00228-023-03479-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036980/
https://www.ncbi.nlm.nih.gov/pubmed/36961578
http://dx.doi.org/10.1007/s00228-023-03479-3

Ejemplares similares